The Food and Drug Administration (FDA) approved Tecentriq (atezolizumab) in combination with chemotherapy on Oct. 8 as an ...

On Oct. 8, 2026, the Food and Drug Administration approved atezolizumab, sold as Tecentriq by Genentech, together with chemotherapy for adults and children as young as two with Stage III colon cancer ...

The FDA has approved atezolizumab plus chemotherapy as an adjuvant treatment for patients aged 2 years and older with stage ...

The Food and Drug Administration (FDA) has approved the immunotherapy drug atezolizumab in combination with chemotherapy for ...

Colon cancer is the third most prevalent form of cancer in the U.S., and its incidence is increasing among younger adults, particularly those younger than 50. While colon cancer screening has helped ...

ROCHESTER, Minn. — Colon cancer is the third most prevalent form of cancer in the U.S., and its incidence is increasing among younger adults, particularly those younger than 50. While colon cancer ...

Neoadjuvant chemotherapy did not improve disease-free survival compared with upfront surgery in patients with locally advanced colon cancer in a randomized trial. However, neoadjuvant chemotherapy did ...

The phase 2 PEGASUS trial of ctDNA-guided adjuvant therapy in high-risk stage II/III colon cancer missed its primary end ...

Just weeks after her 17th birthday, Danielle was diagnosed with stage three colon cancer - the start of a 25-year battle in ...

Colorectal carcinoma (CRC) is one of the most prevalent malignant tumors globally, with high morbidity and mortality rates. 5-Fluorouracil (5-FU) remains the standard ...

The results of the phase 3 ATOMIC trial fired another volley in the ongoing debate over adjuvant vs neoadjuvant immunotherapy for patients with locally advanced colon cancer. But experts are divided ...

“I just immediately thought, ‘What a wonderful life I’ve had,’ ” the 67-year-old said ...